1.1
Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:
-
the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
-
the company provides dupilumab according to the commercial arrangement.